Diabetic nephropathy (DN) is the main cause of end-stage renal disease (ESRD), which is characterized by a series of abnormal changes such as glomerulosclerosis, podocyte loss, renal tubular atrophy ...

Diabetic nephropathy (DN) and diabetic retinopathy (DR) are microvascular complications of diabetes. Microvascular endothelial cells are thought to be the major targets of hyperglycemic injury. In ...

Scientist develop new equation for detecting hyperfiltration that incorporates age but not body surface area. Read more!

The global diabetic nephropathy market was valued at $1.9 billion in 2021, and is projected to reach $3.3 billion by 2031, growing at a CAGR of 6%. PORTLAND, OR, UNITED STATES, January 30, 2025 ...

The National Institute for Nephrology Dialysis and Transplantation (NINDT) has planned a series of events to mark this ...

AI has demonstrated considerable potential in diabetic foot (DF) management. AI-powered thermal imaging and predictive ...

Tonabersat is under clinical development by Inflammx Therapeutics and currently in Phase II for Diabetic Nephropathy. According to GlobalData, Phase II drugs for Diabetic Nephropathy have a 28% phase ...

The researchers tested PEITC in rats that had diabetic nephropathy. Their results showed evidence that PEITC may help repair ...

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. AP-303 is under development for the treatment of diabetic kidney ...